Biotech IV Monitor

GRFS — Grifols S.A.

$5.2B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Grifols S.A., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is September 2027.

Next readoutSeptember 2027in ~10 months
Upcoming readouts55 Phase 3
Market cap$5.2B

Upcoming readouts

Phase 3 Alpha-1 15%
Alpha 1 Antitrypsin Deficiency · NCT07555483
September 2027
Recruiting
Phase 3 Gamunex-C
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) · NCT07540221
December 2027
Recruiting
Phase 3 Gamunex-C, 10% Injectable Solution
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma · NCT07582432
August 2028
Recruiting
Phase 3 Alpha-1 MP
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency · NCT02796937
September 2028
Enrolling
Phase 3 Xembify
Hypogammaglobulinemia; Bacterial Infections · NCT05645107
August 2029
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow GRFS, you can start the conversation.
Track GRFS in real time
See live implied volatility for GRFS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on GRFS
Contact — questions or corrections about GRFS: dukeupt@gmail.com